Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

NK Response Correlates with HIV Decrease in Pegylated IFN-α2a-Treated Antiretroviral Therapy-Suppressed Subjects.

Papasavvas E, Azzoni L, Kossenkov AV, Dawany N, Morales KH, Fair M, Ross BN, Lynn K, Mackiewicz A, Mounzer K, Tebas P, Jacobson JM, Kostman JR, Showe L, Montaner LJ.

J Immunol. 2019 Jun 28. pii: ji1801511. doi: 10.4049/jimmunol.1801511. [Epub ahead of print]

PMID:
31253727
2.

Galectin-9 Mediates HIV Transcription by Inducing TCR-Dependent ERK Signaling.

Colomb F, Giron LB, Premeaux TA, Mitchell BI, Niki T, Papasavvas E, Montaner LJ, Ndhlovu LC, Abdel-Mohsen M.

Front Immunol. 2019 Feb 20;10:267. doi: 10.3389/fimmu.2019.00267. eCollection 2019.

3.

Gene expression profiling informs HPV cervical histopathology but not recurrence/relapse after LEEP in ART-suppressed HIV+HPV+ women.

Papasavvas E, Kossenkov AV, Azzoni L, Zetola NM, Mackiewicz A, Ross BN, Fair M, Vadrevu S, Ramogola-Masire D, Sanne I, Firnhaber C, Montaner LJ.

Carcinogenesis. 2019 Apr 29;40(2):225-233. doi: 10.1093/carcin/bgy149.

PMID:
30364933
4.

Analytical antiretroviral therapy interruption does not irreversibly change preinterruption levels of cellular HIV.

Papasavvas E, Lada SM, Joseph J, Yin X, Liu Q, Azzoni L, Mounzer K, Kostman JR, Richman D, Montaner LJ.

AIDS. 2018 Aug 24;32(13):1763-1772. doi: 10.1097/QAD.0000000000001909.

PMID:
30045057
5.

A preclinical model to investigate the role of surgically-induced inflammation in tumor responses to intraoperative photodynamic therapy.

Davis RW 4th, Papasavvas E, Klampatsa A, Putt M, Montaner LJ, Culligan MJ, McNulty S, Friedberg JS, Simone CB 2nd, Singhal S, Albelda SM, Cengel KA, Busch TM.

Lasers Surg Med. 2018 Jul;50(5):440-450. doi: 10.1002/lsm.22934. Epub 2018 May 25.

6.

Frontline Science: Plasma and immunoglobulin G galactosylation associate with HIV persistence during antiretroviral therapy.

Vadrevu SK, Trbojevic-Akmacic I, Kossenkov AV, Colomb F, Giron LB, Anzurez A, Lynn K, Mounzer K, Landay AL, Kaplan RC, Papasavvas E, Montaner LJ, Lauc G, Abdel-Mohsen M.

J Leukoc Biol. 2018 Sep;104(3):461-471. doi: 10.1002/JLB.3HI1217-500R. Epub 2018 Apr 6.

PMID:
29633346
7.

HCV viraemia associates with NK cell activation and dysfunction in antiretroviral therapy-treated HIV/HCV-co-infected subjects.

Papasavvas E, Azzoni L, Yin X, Liu Q, Joseph J, Mackiewicz A, Ross B, Lynn KM, Jacobson JM, Mounzer K, Kostman JR, Montaner LJ.

J Viral Hepat. 2017 Oct;24(10):865-876. doi: 10.1111/jvh.12714. Epub 2017 May 11.

8.

High-risk oncogenic HPV genotype infection associates with increased immune activation and T cell exhaustion in ART-suppressed HIV-1-infected women.

Papasavvas E, Surrey LF, Glencross DK, Azzoni L, Joseph J, Omar T, Feldman MD, Williamson AL, Siminya M, Swarts A, Yin X, Liu Q, Firnhaber C, Montaner LJ.

Oncoimmunology. 2016 Jan 19;5(5):e1128612. doi: 10.1080/2162402X.2015.1128612. eCollection 2016 May.

9.

Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy.

Sterman DH, Alley E, Stevenson JP, Friedberg J, Metzger S, Recio A, Moon EK, Haas AR, Vachani A, Katz SI, Sun J, Heitjan DF, Hwang WT, Litzky L, Yearley JH, Tan KS, Papasavvas E, Kennedy P, Montaner LJ, Cengel KA, Simone CB 2nd, Culligan M, Langer CJ, Albelda SM.

Clin Cancer Res. 2016 Aug 1;22(15):3791-800. doi: 10.1158/1078-0432.CCR-15-2133. Epub 2016 Mar 11.

10.

Early ART Results in Greater Immune Reconstitution Benefits in HIV-Infected Infants: Working with Data Missingness in a Longitudinal Dataset.

Azzoni L, Barbour R, Papasavvas E, Glencross DK, Stevens WS, Cotton MF, Violari A, Montaner LJ.

PLoS One. 2015 Dec 15;10(12):e0145320. doi: 10.1371/journal.pone.0145320. eCollection 2015.

11.

Plasmacytoid dendritic cell and functional HIV Gag p55-specific T cells before treatment interruption can inform set-point plasma HIV viral load after treatment interruption in chronically suppressed HIV-1(+) patients.

Papasavvas E, Foulkes A, Yin X, Joseph J, Ross B, Azzoni L, Kostman JR, Mounzer K, Shull J, Montaner LJ.

Immunology. 2015 Jul;145(3):380-90. doi: 10.1111/imm.12452. Epub 2015 May 19.

12.

Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients.

Stevenson JP, Kindler HL, Papasavvas E, Sun J, Jacobs-Small M, Hull J, Schwed D, Ranganathan A, Newick K, Heitjan DF, Langer CJ, McPherson JM, Montaner LJ, Albelda SM.

Oncoimmunology. 2013 Aug 1;2(8):e26218. Epub 2013 Aug 27.

13.

Improved treatment for primary HIV infection by interferon-alfa therapy? Does HCV treatment in HIV/HCV coinfected patients help us to test this hypothesis? Reply to zur Wiesch and van Lunzen.

Azzoni L, Foulkes AS, Papasavvas E, Mexas AM, Lynn KM, Mounzer K, Tebas P, Jacobson JM, Frank I, O'Doherty U, Kostman J, Montaner LJ.

J Infect Dis. 2013 Jul 15;208(2):363. doi: 10.1093/infdis/jit160. Epub 2013 Apr 9. No abstract available.

PMID:
23570845
14.

Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV.

Tebas P, Stein D, Binder-Scholl G, Mukherjee R, Brady T, Rebello T, Humeau L, Kalos M, Papasavvas E, Montaner LJ, Schullery D, Shaheen F, Brennan AL, Zheng Z, Cotte J, Slepushkin V, Veloso E, Mackley A, Hwang WT, Aberra F, Zhan J, Boyer J, Collman RG, Bushman FD, Levine BL, June CH.

Blood. 2013 Feb 28;121(9):1524-33. doi: 10.1182/blood-2012-07-447250. Epub 2012 Dec 20. Erratum in: Blood. 2014 Jul 24;124(4):663.

15.

Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration.

Azzoni L, Foulkes AS, Papasavvas E, Mexas AM, Lynn KM, Mounzer K, Tebas P, Jacobson JM, Frank I, Busch MP, Deeks SG, Carrington M, O'Doherty U, Kostman J, Montaner LJ.

J Infect Dis. 2013 Jan 15;207(2):213-22. doi: 10.1093/infdis/jis663. Epub 2012 Oct 26.

16.

Concurrent measures of total and integrated HIV DNA monitor reservoirs and ongoing replication in eradication trials.

Mexas AM, Graf EH, Pace MJ, Yu JJ, Papasavvas E, Azzoni L, Busch MP, Di Mascio M, Foulkes AS, Migueles SA, Montaner LJ, O'Doherty U.

AIDS. 2012 Nov 28;26(18):2295-306. doi: 10.1097/QAD.0b013e32835a5c2f.

17.

Increased CD34+/KDR+ cells are not associated with carotid artery intima-media thickness progression in chronic HIV-positive subjects.

Papasavvas E, Hsue P, Reynolds G, Pistilli M, Hancock A, Martin JN, Deeks SG, Montaner LJ.

Antivir Ther. 2012;17(3):557-63. doi: 10.3851/IMP2013. Epub 2011 Dec 16.

18.

Metabolic and anthropometric parameters contribute to ART-mediated CD4+ T cell recovery in HIV-1-infected individuals: an observational study.

Azzoni L, Foulkes AS, Firnhaber C, Yin X, Crowther NJ, Glencross D, Lawrie D, Stevens W, Papasavvas E, Sanne I, Montaner LJ.

J Int AIDS Soc. 2011 Jul 29;14:37. doi: 10.1186/1758-2652-14-37.

19.

A trial of intrapleural adenoviral-mediated Interferon-α2b gene transfer for malignant pleural mesothelioma.

Sterman DH, Haas A, Moon E, Recio A, Schwed D, Vachani A, Katz SI, Gillespie CT, Cheng G, Sun J, Papasavvas E, Montaner LJ, Heitjan DF, Litzky L, Friedberg J, Culligan M, June CH, Carroll RG, Albelda SM.

Am J Respir Crit Care Med. 2011 Dec 15;184(12):1395-9. doi: 10.1164/rccm.201103-0554CR. Epub 2011 Jun 3.

20.

Increased microbial translocation in ≤ 180 days old perinatally human immunodeficiency virus-positive infants as compared with human immunodeficiency virus-exposed uninfected infants of similar age.

Papasavvas E, Azzoni L, Foulkes A, Violari A, Cotton MF, Pistilli M, Reynolds G, Yin X, Glencross DK, Stevens WS, McIntyre JA, Montaner LJ.

Pediatr Infect Dis J. 2011 Oct;30(10):877-82. doi: 10.1097/INF.0b013e31821d141e.

21.

Association between HIV replication and serum leptin levels: an observational study of a cohort of HIV-1-infected South African women.

Azzoni L, Crowther NJ, Firnhaber C, Foulkes AS, Yin X, Glencross D, Gross R, Kaplan MD, Papasavvas E, Schulze D, Stevens W, van der Merwe T, Waisberg R, Sanne I, Montaner LJ.

J Int AIDS Soc. 2010 Sep 7;13:33. doi: 10.1186/1758-2652-13-33.

22.

Retention of functional DC-NK cross-talk following up to 18 weeks therapy interruptions in chronically suppressed HIV type 1+ subjects.

Papasavvas E, Chehimi J, Azzoni L, Pistilli M, Thiel B, Mackiewicz A, Creer S, Mounzer K, Kostman JR, Montaner LJ.

AIDS Res Hum Retroviruses. 2010 Oct;26(10):1047-9. doi: 10.1089/aid.2010.0020. Epub 2010 Aug 18. No abstract available.

23.

Increased metallothionein gene expression, zinc, and zinc-dependent resistance to apoptosis in circulating monocytes during HIV viremia.

Raymond AD, Gekonge B, Giri MS, Hancock A, Papasavvas E, Chehimi J, Kossenkov AV, Nicols C, Yousef M, Mounzer K, Shull J, Kostman J, Showe L, Montaner LJ.

J Leukoc Biol. 2010 Sep;88(3):589-96. doi: 10.1189/jlb.0110051. Epub 2010 Jun 15. Erratum in: J Leukoc Biol. 2010 Nov;88(5):1061. Kossevkov, Andrew V [corrected to Kossenkov, Andrew V]. J Leukoc Biol. 2010 Nov;88(5):1061a.

24.

Inability of plasmacytoid dendritic cells to directly lyse HIV-infected autologous CD4+ T cells despite induction of tumor necrosis factor-related apoptosis-inducing ligand.

Chehimi J, Papasavvas E, Tomescu C, Gekonge B, Abdulhaqq S, Raymond A, Hancock A, Vinekar K, Carty C, Reynolds G, Pistilli M, Mounzer K, Kostman J, Montaner LJ.

J Virol. 2010 Mar;84(6):2762-73. doi: 10.1128/JVI.01350-09. Epub 2009 Dec 30.

25.

Evidence of a decrease in CD4 recovery once back on antiretroviral therapy after sequential > or =6 weeks antiretroviral therapy interruptions.

Papasavvas E, Foulkes A, Li X, Kostman JR, Mounzer KC, Montaner LJ.

J Acquir Immune Defic Syndr. 2009 Mar 1;50(3):334-5. doi: 10.1097/QAI.0b013e3181966b0c. No abstract available.

26.

Delayed loss of control of plasma lipopolysaccharide levels after therapy interruption in chronically HIV-1-infected patients.

Papasavvas E, Pistilli M, Reynolds G, Bucki R, Azzoni L, Chehimi J, Janmey PA, DiNubile MJ, Ondercin J, Kostman JR, Mounzer KC, Montaner LJ.

AIDS. 2009 Jan 28;23(3):369-75. doi: 10.1097/QAD.0b013e32831e9c76.

27.

HIV type 1 viremia on ART is positively associated with polyclonal T cell proliferation in subjects with T cell IFN-gamma secretion levels comparable to those of uninfected subjects.

Papasavvas E, Moore EC, Sun J, Azzoni L, Pistilli M, Mounzer K, Shull J, Kostman JR, Montaner LJ.

AIDS Res Hum Retroviruses. 2008 Sep;24(9):1203-8. doi: 10.1089/aid.2008.0054.

28.
29.

HIV-1-specific CD4+ T cell responses in chronically HIV-1 infected blippers on antiretroviral therapy in relation to viral replication following treatment interruption.

Papasavvas E, Kostman JR, Thiel B, Pistilli M, Mackiewicz A, Foulkes A, Gross R, Jordan KA, Nixon DF, Grant R, Poulin JF, McCune JM, Mounzer K, Montaner LJ.

J Clin Immunol. 2006 Jan;26(1):40-54.

PMID:
16418802
30.

IL-13 acutely augments HIV-specific and recall responses from HIV-1-infected subjects in vitro by modulating monocytes.

Papasavvas E, Sun J, Luo Q, Moore EC, Thiel B, MacGregor RR, Minty A, Mounzer K, Kostman JR, Montaner LJ.

J Immunol. 2005 Oct 15;175(8):5532-40.

31.

Randomized, controlled trial of therapy interruption in chronic HIV-1 infection.

Papasavvas E, Kostman JR, Mounzer K, Grant RM, Gross R, Gallo C, Azzoni L, Foulkes A, Thiel B, Pistilli M, Mackiewicz A, Shull J, Montaner LJ.

PLoS Med. 2004 Dec;1(3):e64. Epub 2004 Dec 28.

32.

Lessons learned from HIV treatment interruption: safety, correlates of immune control, and drug sparing.

Azzoni L, Papasavvas E, Montaner LJ.

Curr HIV Res. 2003 Jul;1(3):329-42. Review.

PMID:
15046257
33.

Limited magnitude and breadth in the HLA-A2-restricted CD8 T-Cell response to Nef in children with vertically acquired HIV-1 infection.

Chandwani R, Jordan KA, Shacklett BL, Papasavvas E, Montaner LJ, Rosenberg MG, Nixon DF, Sandberg JK.

Scand J Immunol. 2004 Jan;59(1):109-14.

34.

Lack of persistent drug-resistant mutations evaluated within and between treatment interruptions in chronically HIV-1-infected patients.

Papasavvas E, Grant RM, Sun J, Mackiewicz A, Pistilli M, Gallo C, Kostman JR, Mounzer K, Shull J, Montaner LJ.

AIDS. 2003 Nov 7;17(16):2337-43.

PMID:
14571185
35.

Presence of human immunodeficiency virus-1-specific CD4 and CD8 cellular immune responses in children with full or partial virus suppression.

Papasavvas E, Sandberg JK, Rutstein R, Moore EC, Mackiewicz A, Thiel B, Pistilli M, June RR, Jordan KA, Gross R, Maino VC, Nixon DF, Montaner LJ.

J Infect Dis. 2003 Sep 15;188(6):873-82. Epub 2003 Sep 4. Erratum in: J Infect Dis. 2003 Dec 15;188(12):1961.

PMID:
12964119
36.

Sustained impairment of IFN-gamma secretion in suppressed HIV-infected patients despite mature NK cell recovery: evidence for a defective reconstitution of innate immunity.

Azzoni L, Papasavvas E, Chehimi J, Kostman JR, Mounzer K, Ondercin J, Perussia B, Montaner LJ.

J Immunol. 2002 Jun 1;168(11):5764-70.

37.

Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals.

Chehimi J, Campbell DE, Azzoni L, Bacheller D, Papasavvas E, Jerandi G, Mounzer K, Kostman J, Trinchieri G, Montaner LJ.

J Immunol. 2002 May 1;168(9):4796-801.

38.

HIV-1 Vpr regulates expression of beta chemokines in human primary lymphocytes and macrophages.

Muthumani K, Kudchodkar S, Papasavvas E, Montaner LJ, Weiner DB, Ayyavoo V.

J Leukoc Biol. 2000 Sep;68(3):366-72.

PMID:
10985253
39.

Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption.

Papasavvas E, Ortiz GM, Gross R, Sun J, Moore EC, Heymann JJ, Moonis M, Sandberg JK, Drohan LA, Gallagher B, Shull J, Nixon DF, Kostman JR, Montaner LJ.

J Infect Dis. 2000 Sep;182(3):766-75. Epub 2000 Aug 17.

PMID:
10950770
40.

Inhibition of IL-12 production in human monocyte-derived macrophages by TNF.

Ma X, Sun J, Papasavvas E, Riemann H, Robertson S, Marshall J, Bailer RT, Moore A, Donnelly RP, Trinchieri G, Montaner LJ.

J Immunol. 2000 Feb 15;164(4):1722-9.

Supplemental Content

Loading ...
Support Center